Amgen (AMGN) : Fragasso Group scooped up 200 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 12, 2016. The investment management firm now holds a total of 20,432 shares of Amgen which is valued at $3,279,745.Amgen makes up approximately 1.20% of Fragasso Group’s portfolio.
Other Hedge Funds, Including , Cornerstone Investment Partners added AMGN to its portfolio by purchasing 2,428 company shares during the most recent quarter which is valued at $389,743. Amgen makes up approx 0.01% of Cornerstone Investment Partners’s portfolio.Central Bank Trust Co reduced its stake in AMGN by selling 92 shares or 0.75% in the most recent quarter. The Hedge Fund company now holds 12,103 shares of AMGN which is valued at $1,942,774. Amgen makes up approx 0.55% of Central Bank Trust Co’s portfolio.Centurylink Investment Management Co boosted its stake in AMGN in the latest quarter, The investment management firm added 2,664 additional shares and now holds a total of 19,086 shares of Amgen which is valued at $3,074,755. Amgen makes up approx 1.08% of Centurylink Investment Management Co’s portfolio.Integrated Investment Consultants boosted its stake in AMGN in the latest quarter, The investment management firm added 2,200 additional shares and now holds a total of 4,841 shares of Amgen which is valued at $746,821. Amgen makes up approx 0.39% of Integrated Investment Consultants’s portfolio.Cullinan Associates Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 10,680 additional shares and now holds a total of 71,400 shares of Amgen which is valued at $11,015,592. Amgen makes up approx 0.90% of Cullinan Associates Inc’s portfolio.
Amgen opened for trading at $163.45 and hit $164.57 on the upside on Friday, eventually ending the session at $163.28, with a gain of 0.33% or 0.54 points. The heightened volatility saw the trading volume jump to 31,79,693 shares. Company has a market cap of $122,659 M.
On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.
Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.